Victory Capital Management Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Spyre Therapeutics has a 52 week low of $17.24 and a 52 week high of $47.97. The business’s fifty day simple moving average is $21.65 and its 200-day simple moving average is $26.41.

Spyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spyre Therapeutics, Inc. faces ...

Multi-modal AI support, faster chips and AI accelerators are among forthcoming mainframe upgrades that promise big changes.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic ...

Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations ...

Goldman Sachs analyst Paul Choi initiated Spyre Therapeutics (SYRE) with an early-stage biotech designation. The firm sees an “attractive mix of clinically validated targets” and long-acting ...

Wedbush analyst David Nierengarten maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of ...

Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Spyre Therapeutics, Inc. (SYRE) on Thursday reported a loss of $56.3 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...